09:10 AM EDT, 06/25/2024 (MT Newswires) -- Werewolf Therapeutics ( HOWL ) said Tuesday that initial results showed that potential non-Hodgkin lymphoma treatment WTX-330 increased therapeutic window in a phase 1 clinical trial.

The company also said that WTX-330 showed encouraging signals of clinical activity and strong activation of immune biomarkers.

On tolerability, the company said all patients experienced mild to moderate treatment-related toxicities, such as fever and chills, mainly related to the first dose.

Shares of Werewolf Therapeutics ( HOWL ) rose 6.5% in premarket activity.

Price: 2.78, Change: +0.17, Percent Change: +6.51